The CLDN18-ARHGAP fusion GC-bearing model constructed by Wang et al. in 2022 revealed that PI3K inhibitors (PI3Kis) can partially reverse the inhibitory TIME induced by CLDN18-ARHGAP26 fusion, thereby inhibiting tumor growth [92]. Here, CLDN18 is linked to neoplasm.